The Retinoid Conversion Ladder
Vitamin A in skincare exists on a conversion ladder. At the top is retinoic acid, the biologically active form that binds to nuclear receptors in skin cells and directs cellular behaviour. Retinoic acid is available by prescription under the names tretinoin and all-trans retinoic acid. It works, without question. It also causes significant irritation, dryness, peeling, and photosensitivity in most users, which is why it is a prescription drug rather than an over-the-counter cosmetic ingredient.
Below retinoic acid on the ladder sits retinaldehyde, sometimes called retinal. Retinaldehyde is one enzymatic conversion step away from retinoic acid. The enzyme that performs this conversion, retinaldehyde dehydrogenase, is present in skin cells. This means that when retinaldehyde is applied to the skin, it converts to retinoic acid locally, at the site of action, without the systemic exposure that comes with prescription tretinoin.
Below retinaldehyde sits retinol. Retinol requires two enzymatic conversions to reach retinoic acid. First, it must be converted to retinaldehyde by alcohol dehydrogenase or retinol dehydrogenase. Then, the resulting retinaldehyde undergoes the second conversion to retinoic acid. Two steps means more time, more opportunity for degradation before the active form is reached, and lower efficiency overall.
What the Two-Step vs One-Step Difference Means in Practice
The practical consequence of needing one enzymatic conversion versus two is not merely academic. The conversion from retinol to retinaldehyde is the rate-limiting step in the pathway. It is slow and incomplete. Studies comparing equimolar concentrations of retinaldehyde and retinol applied to skin have shown that retinaldehyde produces higher local concentrations of retinoic acid at the receptor sites. In other words, more of the applied active ingredient reaches the form that actually does the work.
This means that a product formulated with retinaldehyde does not need to use as high a starting concentration to achieve the same level of biological activity as a retinol product. The clinical implication is that retinaldehyde can produce results that compare more favourably with prescription tretinoin than retinol can, while remaining in the over-the-counter cosmetic category and producing a tolerability profile that is manageable for most skin types.
The Irritation Profile Comparison
Retinoic acid, applied directly to skin at therapeutic concentrations, irritates almost universally. Retinol, because it requires two conversions before reaching retinoic acid, produces less local retinoic acid at any given moment. This is why it causes less irritation at equivalent application concentrations. The trade-off is reduced efficacy per unit of active ingredient applied.
Retinaldehyde sits between the two. It produces more local retinoic acid than retinol, but the conversion is still a step removed from direct receptor activation. Studies on retinaldehyde irritation consistently show a tolerability advantage over tretinoin at comparable biological activity levels.
Encapsulation adds a further dimension to this tolerability calculation. When retinaldehyde is encapsulated in a time-release delivery system, it is not deposited on the skin all at once. A 1% encapsulated vitamin A releases gradually across 8 to 12 hours, which means that the peak concentration present at the skin surface at any given moment is a fraction of the total dose. The slow-release mechanism reduces the acute irritation response and extends the window of active receptor engagement. It is the formulation approach that allows 1% retinaldehyde to be used twice daily across all skin types, including sensitive.
Stability Considerations
Retinoids are notoriously unstable molecules. Retinoic acid, retinaldehyde, and retinol all oxidise on exposure to air, light, and heat. Once oxidised, they lose biological activity. Retinaldehyde is more unstable than retinol because its aldehyde group is more reactive. This stability challenge has historically been cited as a reason not to use retinaldehyde in cosmetic formulations.
Encapsulation solves this problem directly. When retinaldehyde is enclosed in a protective delivery system, it is shielded from oxidative exposure until it is released at the skin surface. The active ingredient reaches the skin in its intended chemical form rather than as a degraded byproduct. Packaging also matters significantly. Products containing retinaldehyde should be in airless, opaque containers that minimise oxygen and light exposure. Airless pump dispensers, particularly in dark or opaque packaging, preserve retinoid potency far better than jar packaging, which exposes the product to air every time it is opened.
Selecting the Right Vitamin A for Your Skin
For skin that has never used vitamin A, starting with a lower concentration of encapsulated retinaldehyde in a formula that also contains barrier-supporting ingredients is the most sensible approach. The encapsulation manages the tolerability, the barrier ingredients reduce the risk of irritation compounding any disruption, and the clinical dose is meaningful rather than cosmetic.
For skin that is experienced with retinol and not seeing further progress, switching to retinaldehyde at a comparable or slightly lower concentration often produces a more pronounced effect, because the one-step conversion delivers more retinoic acid to the receptors from the same starting material.
For skin that has tried prescription tretinoin and found it too irritating, encapsulated retinaldehyde is often the closest accessible alternative, producing comparable biological activity through the same receptor pathway without the peak-dose irritation that comes from direct retinoic acid application.
The Repair and Refine ABC Serum from Rejuvaus professional-grade skincare is formulated with 1% encapsulated vitamin A alongside 10% encapsulated vitamin B3 and 5% vitamin C superfruit extract. The combination addresses pigmentation, cellular renewal, and barrier support simultaneously, with slow-release encapsulation making it accessible for twice-daily use.
